Main content area

Report of the 2014 Cent Gardes HIV Vaccine Conference—Part 2: Cell-mediated immunity, mucosal protection, and clinical trials

Girard, Marc P., Picot, Valentina, Longuet, Christophe, Nabel, Gary J.
Vaccine 2015 v.33 no.33 pp. 4051-4055
HIV infections, Human immunodeficiency virus, T-lymphocytes, cell-mediated immunity, clinical trials, immunization, immunoglobulin A, monkeys, mucosal immunity, neutralizing antibodies, people, vaccines, viruses
The 2014 Cent Gardes Conference took place on October 5–7, 2014, at the Fondation Mérieux Conference Center, on the shores of the Annecy Lake and aimed to review the progress and promise of HIV vaccines. The elicitation of broadly neutralizing antibodies (bNAbs), their use in passive immunization, as well as their genetic delivery (vector immunoprophylaxis) by a recombinant Adenovirus-associated virus (AAV) vector were reviewed in a preceding article [1]. Approaches to the elicitation of long-lasting T cell or mucosal immunity were also discussed and are now reviewed here. The possibility of eliciting mucosal IgAs was discussed, since it was demonstrated that transcytosis-blocking IgAs can protect monkeys against repeated vaginal challenge with a pathogenic chimeric simian and human immunodeficiency virus (SHIV). The possibility of purging the HIV reservoirs from HIV-infected persons and developing a cure of the disease was also discussed.